San Diego, Calif., June 16, 2023 – Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing effective and differentiated cellular immunotherapies based on induced pluripotent stem cells (iPSCs) derived natural killer cells (iNK) and macrophages (iMACs), today announced the appointment of Steve Potter as Vice President, People and Culture.
Mr. Potter has over 25 years of experience leading people and culture, human capital management and talent management for companies in biotech, biopharma and high technology. In his new role, Mr. Potter will be responsible for leading Shoreline’ People and Culture Team and will serve as a key member of the Executive Team.
“Steve is a proven leader in building and maintaining thriving company cultures and has an impressive track record in attracting and retaining world-class talent in biotechnology companies at our stage of growth,” said Kleanthis G. Xanthopoulos, Ph.D., Shoreline’s Chairman and CEO. “We are thrilled to have Steve join our Executive team as we work to win the war on cancer with our pipeline of differentiated immunotherapies.”
Prior to joining Shoreline, Mr. Potter served as the Vice President of People and Culture at Artiva Biotherapeutics, where he played a key role in establishing its culture and led the Company’s growth. Prior to that, Mr. Potter held people and culture leadership roles at Intercept Pharmaceuticals, Element Biosciences and Amylin Pharmaceuticals. Mr. Potter received his MS in Organization Development and Human Resources from the University of San Francisco and received a BS in Business from University of Sacramento. He is a founding board member of the San Diego Human Resources Forum and currently serves on its board.
Mr. Potter commented, “I am excited to join Shoreline at this key phase in its development, with the most sophisticated and differentiated cellular design and gene editing technologies in the field. Shoreline’s people are vital to realizing our mission of bringing novel immunotherapies to patients with cancer, and I look forward to fostering a vibrant and diverse culture to maximize the success of our team.”
About Shoreline Biosciences
Shoreline Biosciences is a biopharmaceutical company developing effective and differentiated cellular immunotherapies based on induced pluripotent stem cells (iPSCs) derived natural killer cells (iNK) and macrophages (iMACs). The company’s cellular design and gene editing technologies are built on a unique understanding of iPSC differentiation, immune cell biology and premier gene editing tools such as SLEEK knock-in technology and access to AsCas12a, a high fidelity and high efficiency engineered CRISPR/CAS endonuclease. Our allogeneic effector cells are designed for durability, scalability, safety, and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company.
For more information, please visit https://shorelinebio.com/ and engage with us on LinkedIn.
Investor Contact:
Amy Conrad
Juniper Point
amy@juniper-point.com
858-366-3243